HOUSTON, Feb. 16, 2021 /PRNewswire/ — Iterion Therapeutics, Inc. ("Iterion"), a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has ...

Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...

Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in ...

FOG-001 targets the β-catenin–TCF interaction, a previously "undruggable" target, offering new hope for desmoid tumor treatment. Early clinical trials show FOG-001 leads to significant tumor shrinkage ...

A long list of drug targets are deemed undruggable, beyond the reach of current drug discovery technologies. A few companies hope to soon cross the β-catenin transcription factor off that list.

Wnt/β-catenin pathway, first identified as a key cancer driver over 30 years ago and implicated in millions of cancer cases annually, is not addressed by any currently approved therapies Oral ...

Volume 11, Issue 26 of Oncotarget reported that in this study the authors studied the differences in mi RNA expression between sporadic and FAP-associated Desmoid tumors using microarray confirmed by ...

Volume 11, Issue 26 of Oncotarget reported that in this study the authors studied the differences in mi RNA expression between sporadic and FAP-associated Desmoid tumors using microarray confirmed by ...

Volume 11, Issue 26 of Oncotarget reported that in this study the authors studied the differences in mi RNA expression between sporadic and FAP-associated Desmoid tumors using microarray confirmed by ...

Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025 Consistent, significant tumor ...